Swiss-listed specialty pharma focused on gastrointestinal drugs and endoscopy technology, using its MMX drug-delivery platform.
Swiss-listed specialty pharma focused on gastrointestinal drugs and endoscopy technology, using its MMX drug-delivery platform.
Moat: narrow (IP / patents). Patented MMX colon-targeted delivery technology licensed to pharma partners.
Headquarters: Zug, Switzerland · Employees: 324
Size Cosmo (CMHC.SW) is a Switzerland Health Care company (Pharmaceuticals: Major) with a market value of $1.13B, the 116th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 55.50 on 18 Nov 2026.
Performance Over six months the shares fell 30.1%, against -9.7% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue fell 44.7% over the last twelve months (peer median +5.9%); the operating margin is -13.3% (peer median 4.5%).
Valuation It trades at 418.7× forward earnings against a peer median of 18.2× (most expensive of 11).
Capital Return on invested capital runs 11.6 points below its cost of capital (8.8% WACC).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 95.0M | CHF 97.6M | CHF 254M | CHF 90.1M | CHF 102M |
| Revenue growth | — | -62% | +182% | -12% | — |
| Gross profit | CHF 43.3M | CHF 45.4M | CHF 209M | CHF 50.3M | CHF 57.8M |
| EBITDA | -CHF 559,550 | CHF 2.19M | CHF 150M | CHF 7.83M | CHF 40.2M |
| Net income | -CHF 5.85M | -CHF 3.38M | CHF 127M | -CHF 10.5M | CHF 17.3M |
| Free cash flow | -CHF 22.5M | -CHF 14.8M | CHF 151M | CHF 15.4M | CHF 26.6M |
| Capital expenditure | CHF 4.64M | CHF 5.12M | CHF 5.39M | CHF 4.27M | CHF 7.34M |
| Total debt | n/a | CHF 3.97M | CHF 2.07M | CHF 1.71M | CHF 178M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Cosmo CMHC.SW | $1.13B | -30% | -45% | -13% | 418.7× | n/a |
| Bausch Health Companies BHC.TO | $3.27B | +66% | +10% | 27% | 2.0× | -14.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CMHC.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.9% | -2.0% | 6th highest of 21 |
| 6-month return | -30.1% | -9.7% | 6th lowest of 20 |
| Distance from 52-week high | -57.1% | -33.1% | 5th lowest of 21 |
| Revenue growth (TTM) | -44.7% | +5.9% | lowest of 18 |
| Operating margin | -13.3% | 4.5% | 9th lowest of 19 |
| Forward P/E | 418.7× | 18.2× | most expensive of 11 |
| ROIC minus cost of capital | -11.6 pp | -4.6 pp | 8th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Cosmo CMHC.SW | Switzerland | $1.13B | -30% | -45% | -13% | 418.7× | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 18.4× | 3.4% | -1.2% |
| GC Biopharma 006280.KS | South Korea | $1.12B | -10% | -3% | 4% | 4.6× | n/a | n/a |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 14.5× | n/a | n/a |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.12B | n/a | n/a | n/a | n/a | n/a | n/a |
| Viyash Scientific VIYASH.NS | India | $1.11B | +3% | +124% | 13% | 32.2× | 36.3% | +20.4% |
| ST Pharm 237690.KS | South Korea | $1.11B | -51% | +26% | 18% | 27.8× | 4.2% | +21.7% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.11B | -7% | -9% | 11% | 18.1× | 4.9% | +11.3% |
| Vetoquinol VETO.PA | France | $1.10B | +19% | -1% | 15% | 15.5× | -3.6% | +4.2% |
| PYC Therapeutics PYC.AX | Australia | $1.09B | +29% | n/a | n/a | n/a | n/a | n/a |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 22.1× | -4.0% | -9.0% |
| MedinCell MEDCL.PA | France | $1.09B | +4% | -23% | -131% | n/a | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | n/a | 1.0% | -4.2% |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 4.3× | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | n/a | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | n/a | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | n/a | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 60.4× | n/a | n/a |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.20B | -46% | +15% | -129% | n/a | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | n/a | 44.1% | -13.2% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | n/a | n/a | n/a |